Latest News & Updates

FDA approves alpelisib for PIK3CA-related overgrowth spectrum
April 6, 2022

Continue Reading »

FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma
April 1, 2022

Continue Reading »

FDA approves Pluvicto for metastatic castration-resistant prostate cancer
March 24, 2022

Continue Reading »

FDA approves Opdualag for unresectable or metastatic melanoma
March 21, 2022

Continue Reading »

FDA approves alpelisib for PIK3CA-related overgrowth spectrum
April 6, 2022

Continue Reading »

FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma
April 1, 2022

Continue Reading »

FDA approves Pluvicto for metastatic castration-resistant prostate cancer
March 24, 2022

Continue Reading »

FDA approves Opdualag for unresectable or metastatic melanoma
March 21, 2022

Continue Reading »

Get More from FLASCO With Your Membership

The Corporate Membership Program allows FLASCO to expand our offerings to our membership. Every FLASCO meeting also provides the industry representative with opportunities to educate our members. When you send representatives to a FLASCO meeting, you are allowing them to share their knowledge, as well as receive the same knowledge as our members by participating within the educational sessions. This helps ensure that the hematology and oncology community at large are learning, sharing best practices, and finding solutions to problems together.

Corporate Members:

Diamond Elite

Diamond

Platinum

Gold

We're Here to Help Contact Us

Contact Us

Add your name, email & message below: